Japan Insulin Drugs Delivery Devices Market to Grow at 2.34% During 2024-2032, Propelled by Rising Prevalence of Diabetes

According to the latest report by IMARC Group, titled “Japan Insulin Drugs Delivery Devices Market Report by Type (Drug, Device), and Region 2024-2032,” the Japan insulin drugs delivery devices market is expected to exhibit a CAGR of 2.34% during the forecast period (2024-2032). Insulin drugs delivery devices are specialized medical tools that enable the controlled and precise delivery of insulin into the body to help regulate glucose levels effectively. They are available in several forms, including pens, pumps, syringes, and jet injectors. They offer ease of use, making it simpler for patients to self-administer insulin injections or infusions, leading to improved adherence to treatment plans. They reduce the hassle and discomfort associated with traditional injection methods, making diabetes management more convenient and less intrusive. They are widely used by pregnant women with gestational diabetes to control their blood sugar levels.

Japan Insulin Drugs Delivery Devices Market Trends:

The rising prevalence of diabetes in Japan represents one of the primary factors driving the demand for improved and more convenient methods of insulin administration. Additionally, the increasing awareness among the masses about the importance of proper insulin delivery and the role of advanced devices in improving overall health outcomes is offering a favorable market outlook in the country. Along with this, the escalating demand for smart insulin pens and insulin pumps equipped with advanced features like Bluetooth connectivity and dose tracking, and integration with smartphone apps, providing patients and healthcare professionals with real-time data and improved control over diabetes management, is facilitating the market growth. Apart from this, continuous technological advancements in insulin drug delivery devices are improving their efficacy and attracting a wider consumer base. Furthermore, governing authorities of the country are actively promoting preventive healthcare measures and diabetes management programs, creating a conducive environment for the growth of the insulin drug delivery devices market. Moreover, rising collaborations and partnerships between pharmaceutical companies, device manufacturers, and healthcare providers in Japan are strengthening the growth of the market.

Market Summary:

• Based on the type, the market has been segmented into drug [Basal Or Long-Acting Insulins {Lantus (Insulin Glargine), Levemir (Insulin Detemir), Toujeo (Insulin Glargine), Tresiba (Insulin Degludec), and Basaglar (Insulin Glargine)}; Bolus or Fast-Acting Insulins {Novorapid/Novolog (Insulin Aspart), Humalog (Insulin Lispro), Apidra (Insulin Glulisine), Fiasp (Insulin Aspart), and Admelog (Insulin Lispro Sanofi)}; Traditional Human Insulins {Novolin/Mixtard/Actrapid/Insulatard, Humulin, and Insuman}; Combination Insulins Novomix (Biphasic Insulin Aspart), Ryzodeg (Insulin Degludec and Insulin Aspart), Xultophy (Insulin Degludec and Liraglutide), and Soliqua/Suliqua (Insulin Glargine and Lixisenatide)}; and Biosimilar Insulins {Insulin Glargine Biosimilars and Human Insulin Biosimilars} and device [insulin pumps {insulin pump devices, insulin pump reservoirs, and insulin infusion sets}; insulin pens {cartridges in reusable pens and disposable insulin pens}; insulin syringes; and insulin jet injectors}].
• Region-wise, the market has been segmented into Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
• The competitive landscape of the market has also been examined in the report, along with the detailed profiles of the major players operating in the industry.

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800